Kalohexis Announces Publication in Nature Communications Highlighting Dual MC3R/MC4R Activation as a Novel, Durable Mechanism that Drives Weight Loss
Dual Activation of MC3R and MC4R Drives Weight Loss and Reduces Food Intake in Male Primates with Obesity NORTHBROOK, Ill., May 29, 2026 /PRNewswire/ -- Kalohexis, a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care...
Dual Activation of MC3R and MC4R Drives Weight Loss and Reduces Food Intake in Male Primates with Obesity NORTHBROOK, Ill., May 29, 2026 /PRNewswire/ -- Kalohexis, a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.